IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

AUSTIN, Texas -- ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENSai™ platform, with a direct comparison to gold-standard wet-lab methods.

IPA reports new results validating in silico epitope mapping application - BioTuesdays

ImmunoPrecise Antibodies (IPA) (NASDAQ:IPA) announced new benchmarking results validating the accuracy and utility of its in silico epitope mapping application—part of the LENSai platform, which delivers x-ray-level epitope mapping insights in hours. According to IPA, the results represent advancement in antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. The LENSai platform matc…